Thursday, April 3, 2025

Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer

Related stories

Amazon simplifies access to Amazon Nova Gen AI models

Work with our foundation models on nova.amazon.com and access...

GE HealthCare & FPT Expand AI Healthcare Partnership

Global IT firm FPT and GE HealthCare announced a...

121G Launches HealthCoach, an AI Chronic Care Platform

121G Consulting proudly announces the release of its AI-based...

Covera Health Unveils ‘Protect Her™’ for Early Detection

New AI-powered platform leverages routine imaging to identify hidden...

Gayle deDie Named Cavallo’s SVP of Marketing

Cavallo, the leader in AI-powered Profit Maximization, announced Gayle...
spot_imgspot_img

Danaher Corporation, a global science and technology innovator, announced the creation of the new role of Chief Data & Artificial Intelligence (AI) Officer and the appointment of Dr. Martin Stumpe to the role.

Jose-Carlos Gutierrez-Ramos, Senior Vice President and Chief Science Officer, Danaher, said: “We are delighted to welcome Dr. Stumpe to our team. His extensive experience in leveraging AI to drive scientific and operational progress will be critical in further supporting Danaher’s AI and data strategy to advance innovation.”

Also Read: SCIEX and Mass Analytica Collaborate to Advance Artificial Intelligence Quantitation Software

Dr. Stumpe most recently served as Chief of AI at Tempus, where he spearheaded AI initiatives aiming to make precision medicine a reality. Prior to Tempus, he founded the Cancer Pathology project at Google – which aimed to enhance the accuracy of cancer detection and grading using AI techniques – and was part of the Kepler team at NASA’s Ames Research Center. Dr. Stumpe holds a Ph.D. in Computational & Theoretical Physics from the Max Planck Institute for Biophysical Chemistry in Germany. He will report to Dr. Gutierrez-Ramos.

Danaher is increasingly focusing on AI through inorganic investment, strengthening internal capabilities, and collaborating with leading academic institutions. In December, the company will host the third annual Danaher Summit, bringing together visionary leaders and innovators to discuss AI’s potential impact on biopharmaceutical research and development.

Source: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img